Albireo Pharma (NASDAQ:ALBO) is scheduled to be announcing its Q3 earnings results before the market opens on Tuesday, November 13th. Analysts expect the company to announce earnings of ($0.97) per share for the quarter.

Shares of ALBO opened at $25.84 on Friday. The stock has a market cap of $332.52 million, a PE ratio of -8.20 and a beta of 1.74. Albireo Pharma has a 52 week low of $21.25 and a 52 week high of $39.87.

ALBO has been the subject of several recent research reports. BidaskClub lowered shares of Albireo Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday, July 18th. Wedbush reissued an “outperform” rating on shares of Albireo Pharma in a research report on Monday, July 16th. Zacks Investment Research raised shares of Albireo Pharma from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a research report on Tuesday, July 24th. Finally, Cowen reissued a “buy” rating on shares of Albireo Pharma in a research report on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Albireo Pharma currently has a consensus rating of “Buy” and an average price target of $59.40.

In other Albireo Pharma news, insider Ronald Harold Wilfred Cooper purchased 788 shares of the company’s stock in a transaction that occurred on Tuesday, August 14th. The stock was purchased at an average price of $31.85 per share, with a total value of $25,097.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 3.60% of the company’s stock.

An institutional investor recently raised its position in Albireo Pharma stock. Bank of New York Mellon Corp grew its position in shares of Albireo Pharma Inc (NASDAQ:ALBO) by 205.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,263 shares of the biopharmaceutical company’s stock after buying an additional 21,685 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.27% of Albireo Pharma worth $1,145,000 as of its most recent filing with the Securities and Exchange Commission. 63.44% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This report was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Recommended Story: Marijuana Stocks Investing Considerations

Earnings History for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with's FREE daily email newsletter.